Get the Stockscreener App
70.44
1.48%
1.03
After Hours:
70.44
Insmed Inc stock is traded at $70.44, with a volume of 4.97M.
It is up +1.48% in the last 24 hours and down -3.07% over the past month.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
See More
Previous Close:
$69.41
Open:
$68.8
24h Volume:
4.97M
Relative Volume:
3.13
Market Cap:
$12.60B
Revenue:
$342.96M
Net Income/Loss:
$-864.29M
P/E Ratio:
-13.37
EPS:
-5.27
Net Cash Flow:
$-636.03M
1W Performance:
-1.66%
1M Performance:
-3.07%
6M Performance:
+8.85%
1Y Performance:
+154.20%
1-Day Range:
$68.80
$71.07
1-Week Range:
$68.67
$75.16
52-Week Range:
$21.92
$80.53
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
70.44 | 12.60B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Principal Financial Group Inc. Has $136.65 Million Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insider Selling: Insmed Incorporated (NASDAQ:INSM) CEO Sells 18,750 Shares of Stock - MarketBeat
Insmed CEO William Lewis sells $1.79 million in stock - Investing.com
Insmed's SWOT analysis: biopharmaceutical firm's stock poised for growth amid challenges - Investing.com
Tidal Investments LLC Buys 19,696 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Geode Capital Management LLC Purchases 172,664 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed CEO William Lewis sells $1.87 million in stock - Investing.com India
Insmed CEO William Lewis sells $1.87 million in stock By Investing.com - Investing.com Australia
Pulmonary Arterial Hypertension Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Novartis, Insmed Inc, Chugai Pharma, Merck Sharp & Dohme, Janssen Pharma, Aerovate - The Globe and Mail
Analysts Set Insmed Incorporated (NASDAQ:INSM) PT at $83.67 - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Position Increased by Orion Portfolio Solutions LLC - MarketBeat
Insmed's SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Canada
Insmed's SWOT analysis: rare disease biotech stock poised for growth - Investing.com
Wellington Management Group LLP Purchases 24,025 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Citizentribune
Should You Invest in Insmed Incorporated (INSM)? - Insider Monkey
Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Castleark Management LLC - MarketBeat
Insmed To Present at December 2024 Investor Conferences - Citizentribune
Soros Fund Management LLC Buys 7,901 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Point72 Asset Management L.P. Sells 5,552,949 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed (LTS:0JAV) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Readystate Asset Management LP Reduces Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
RTW Investments LP Decreases Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Polar Asset Management Partners Inc. - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
INSM (Insmed) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Parkman Healthcare Partners LLC Has $2.59 Million Stock Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Patient Square Capital LP Makes New $12.53 Million Investment in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Bamco Inc. NY Takes Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Cerity Partners LLC Buys 17,869 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Stake Reduced by HighVista Strategies LLC - MarketBeat
Cinctive Capital Management LP Sells 114,851 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Erste Asset Management GmbH Buys New Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Why Is Insmed Incorporated (INSM) Among the Best High Growth Healthcare Stocks to Invest In Now? - Insider Monkey
Insmed to Present at Evercore ISI HealthCONx and Nasdaq Investor Conferences - StockTitan
Bellevue Group AG Reduces Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed (LTS:0JAV) Forward Dividend Yield % : 0.00% (As of Nov. 30, 2024) - GuruFocus.com
Eventide Asset Management LLC Grows Stock Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Vestal Point Capital LP Purchases 850,000 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Incorporated (NASDAQ:INSM) is Suvretta Capital Management LLC's 3rd Largest Position - MarketBeat
Groundbreaking Insights Unveiled in Non-Cystic Fibrosis Bronchiectasis Pipeline Report - GlobeNewswire Inc.
Insmed Incorporated (NASDAQ:INSM) Shares Bought by Ally Bridge Group NY LLC - MarketBeat
Insmed Incorporated (NASDAQ:INSM) is Acuta Capital Partners LLC's 4th Largest Position - MarketBeat
Insmed Insiders Sold US$3.8m Of Shares Suggesting Hesitancy - Simply Wall St
Charles Schwab Investment Management Inc. Raises Stake in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Qsemble Capital Management LP Takes $1.69 Million Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Natixis Advisors LLC Makes New $1.53 Million Investment in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed (LTS:0JAV) 3-Year Revenue Growth Rate : 8.90% (As of Sep. 2024) - GuruFocus.com
Insmed Incorporated (NASDAQ:INSM) Shares Sold by Loomis Sayles & Co. L P - MarketBeat
Westfield Capital Management Co. LP Makes New $18.38 Million Investment in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Intech Investment Management LLC Buys New Shares in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Dec 19 '24 |
Option Exercise |
10.85 |
6,830 |
74,106 |
240,754 |
| Lewis William | Chair and CEO |
Dec 19 '24 |
Sale |
69.91 |
18,750 |
1,310,799 |
384,960 |
| Lewis William | Chair and CEO |
Dec 19 '24 |
Sale |
69.92 |
6,830 |
477,550 |
233,924 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):